SynAct Pharma’s Chairman to BioStock: ”We are confident we have the right strategy”
SynAct Pharma’s Capital Markets Day provided detailed information regarding the revised strategy for its lead asset, resomelagon. The company focuses on the phase IIb ADVANCE study in early, severe rheumatoid arthritis, which is now up and running in the US. In parallel, the company is engaging in partnering discussions to strike a deal for phase III studies and beyond.
– SynAct has a clear strategy, the right team and fresh funding to continue with its plan, says Anders Kronborg, Chairman of the Board.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se